Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 53 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
FUJIREBIO EUROPE from Gent, company number BE0427550660, closed financial year 2026 with a result of € -2.7 million after tax. For that financial year FUJIREBIO EUROPE recorded revenue of € 51.4 million and equity of € 45.7 million. Compared with financial year 2025, the result moved from € 5.2 million to € -2.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
€ 45.7 million
▼ 6% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.7 million
▼ still € 5.2 million profit in 2025
Profit after tax over the fiscal year.
€ 3.4 million
▲ 4% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 14.3 million.
People and assets in 2026
141
▲ 0.6 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 18 million
▲ 2% vs 2025
€ 127,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 429,658
▲ 10% vs 2025
Of which on lease € 2,585.
Debts at end 2026
€ 24.1 million
▼ 20% vs 2025
Loans from banks and other lenders, long and short.
€ 8.2 million
▲ 22% vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 134 days on average.
€ 3.7 million
▼ 4% vs 2025
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 33,269,196 | € 33,970,542 | € 40,111,746 | € 51,395,010 | ▲ 28% |
| Profit after taxes | € -1,808,085 | € -567,132 | € 5,187,093 | € -2,724,989 | ▼ € 7.9 million |
| Equity | € 33,819,086 | € 43,251,954 | € 48,439,047 | € 45,714,058 | ▼ 6% |
| Total debts | € 53,204,127 | € 44,546,994 | € 41,078,916 | € 36,121,292 | ▼ 12% |
| Cash | € 3,479,673 | € 3,534,330 | € 3,297,566 | € 3,444,437 | ▲ 4% |
| Land & buildings | € 449,173 | € 3,219,186 | € 3,894,516 | € 3,916,666 | ▲ 1% |
| Retained profit | € 12,420,764 | € 11,853,632 | € 17,040,725 | € 14,315,736 | ▼ 16% |
| Bank debt | € 41,431,813 | € 31,465,655 | € 30,159,170 | € 24,103,664 | ▼ 20% |
| Balance sheet total | € 87,025,769 | € 87,798,948 | € 89,517,963 | € 81,835,350 | ▼ 9% |
| Employees (FTE) | 128.6 | 134.6 | 140.4 | 141 | ▲ 0.6 |
Key figures of FUJIREBIO EUROPE, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to FUJIREBIO EUROPE?
What happened at FUJIREBIO EUROPE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 2.7 million (▼ € 7.9 million vs 2025). Source: NBB ↗
- TADASHI NINOMIYA stepped down as director. NBB
- KURT TROCH stepped down as director. NBB
- AOKI KOJI stepped down as director. NBB
- CDW Invest BV stepped down as director. NBB
- GOKI ISHIKAWA stepped down as director. NBB
- TADASHI NINOMIYA became a director. NBB
- KURT TROCH became a director. NBB
In short
From € 1.8 million loss in 2023 to € 2.7 million loss in 2026.
Paid € 1.2 million in corporate taxes since 2023.
Best year ever: 2025, with € 5.2 million profit.
Pays suppliers within 134 days on average.
A new publication or filing at FUJIREBIO EUROPE? We notify you, reason included.
Follow FUJIREBIO EUROPEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 100% of Fujirebio Iberia SL, 100% of Fujirebio Germany GmbH, 100% of ADx NeuroSciences NV, 100% of Fujirebio France SARL and 100% of Fujirebio Italia S.r.l. itself.
Directors
According to the 2026 annual accounts
GOKI ISHIKAWA
Director
since 2014 · until 2026
TADASHI NINOMIYA
Director
since 2026 · until 2026
KURT TROCH
Director
since 2022 · until 2026
AOKI KOJI
Director
since 2022 · until 2026
Managing director · represented by Christiaan De Wilde
Also active at: ADx NeuroSciences
since 2022 · until 2026
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 6
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0427.550.660
- VAT number
- BE 0427.550.660
- Registered office
- Technologiepark-Zwijnaarde 6, 9052 Gent
- Names & denominations
- FUJIREBIO EUROPE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 July 1985
- Peppol
- Active · Active since 8 Jan 2026
- Activities · NACE
Vervaardiging van andere chemische producten, neg
Vervaardiging van overige chemische producten
Speur- en ontwikkelingswerk op biotechnologisch gebied